<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40626521</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>10</Issue><PubDate><Year>2025</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Nodal Downstaging in Patients With Rectal Cancer: Survival Is Promising if YpN0 Is Achieved.</ArticleTitle><Pagination><StartPage>1162</StartPage><EndPage>1171</EndPage><MedlinePgn>1162-1171</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003846</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Locally advanced rectal cancer is a critical health concern, with neoadjuvant therapy emerging as a pivotal strategy to enhance survival rates.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aims to evaluate the prognostic value of achieving ypN0 status after neoadjuvant therapy in patients with locally advanced rectal cancer, comparing survival outcomes among natural N0, downstaged N0, and ypN + groups.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">We conducted a post hoc analysis of the FOWARC trial (neoadjuvant FOLFOX6 chemotherapy with or without radiation) using Kaplan-Meier survival analysis and Cox regression models to assess overall survival, disease-free survival, and locoregional recurrence-free survival.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">The multicenter, randomized phase III FOWARC trial was conducted across 15 hospitals in China, adhering to the highest ethical standards.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Our cohort included 449 patients with locally advanced rectal cancer who underwent neoadjuvant chemoradiotherapy followed by total mesorectal excision.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Neoadjuvant chemoradiotherapy followed by total mesorectal excision.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The primary end point was 5-year overall survival, with secondary end points being 3-year disease-free survival and 3-year locoregional recurrence-free survival.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The 5-year overall survival rates for natural N0 and downstaged N0 groups were 88% and 89%, respectively, significantly higher than the 73% observed in the ypN + group ( p = 0.0034). The complete pathological response rate was markedly lower in the ypN + group. Multivariable analysis revealed that the ypN stage is an independent prognostic factor for overall survival.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The study's retrospective design may introduce potential biases in patient selection and preoperative staging.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Achieving ypN0 status via neoadjuvant chemoradiotherapy significantly improves survival in patients with locally advanced rectal cancer, regardless of ypT or cN status. This status not only serves as an independent prognostic factor but may also help guide hypothesis-driven, individualized postoperative treatment strategies. See Video Abstract .</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION" NlmCategory="BACKGROUND">NCT01211210.</AbstractText><AbstractText Label="REDUCCIN DEL ESTADIO NODAL EN PACIENTES CON CNCER RECTAL LA SUPERVIVENCIA ES PROMETEDORA SI SE ALCANZA YPN" NlmCategory="UNASSIGNED">ANTECEDENTES:El c&#xe1;ncer rectal localmente avanzado es un problema de salud cr&#xed;tico, y la terapia neoadyuvante se est&#xe1; imponiendo como una estrategia fundamental para mejorar las tasas de supervivencia.OBJETIVO:El objetivo de este estudio es evaluar el valor pron&#xf3;stico de alcanzar el estado ypN0 tras la terapia neoadyuvante en pacientes con c&#xe1;ncer rectal localmente avanzado, comparando los resultados de supervivencia entre los grupos N0 natural, N0 en estadio inferior y ypN + .DISE&#xd1;O:Realizamos un an&#xe1;lisis post hoc del ensayo FOWARC, empleando el an&#xe1;lisis de supervivencia de Kaplan-Meier y modelos de regresi&#xf3;n de Cox para evaluar la supervivencia global, la supervivencia libre de enfermedad y la supervivencia libre de recidiva locorregional.ENTORNO:El ensayo multic&#xe9;ntrico y aleatorizado de fase III FOWARC se llev&#xf3; a cabo en 15 hospitales de China, respetando las normas &#xe9;ticas.PACIENTES:Nuestra cohorte incluy&#xf3; a 449 pacientes con c&#xe1;ncer rectal localmente avanzado que se sometieron a quimiorradioterapia neoadyuvante seguida de extirpaci&#xf3;n mesorrectal total.INTERVENCIONES:Quimiorradioterapia neoadyuvante seguida de extirpaci&#xf3;n mesorrectal total.PRINCIPALES MEDIDAS DE RESULTADO:El criterio de valoraci&#xf3;n principal fue la supervivencia global a 5 a&#xf1;os, y los criterios de valoraci&#xf3;n secundarios fueron la supervivencia libre de enfermedad a 3 a&#xf1;os y la supervivencia libre de recidiva locorregional a 3 a&#xf1;os.RESULTADOS:La supervivencia global a 5 a&#xf1;os para los grupos N0 natural y N0 en estadio inferior fue del 88 % y del 89 %, respectivamente, significativamente superior al 73 % observado en el grupo ypN + ( p = 0,0034). La tasa de respuesta patol&#xf3;gica completa fue notablemente inferior en el grupo ypN + . El an&#xe1;lisis multivariable mostr&#xf3; que el estadio ypN era un factor pron&#xf3;stico independiente para la supervivencia global.LIMITACIONES:El dise&#xf1;o retrospectivo del estudio puede introducir sesgos potenciales en la selecci&#xf3;n de pacientes y la estadificaci&#xf3;n preoperatoria.CONCLUSIONES:Alcanzar el estado ypN0 mediante quimiorradioterapia neoadyuvante mejora significativamente la supervivencia en pacientes con c&#xe1;ncer rectal localmente avanzado, independientemente del estado ypT o cN. Este estado no solo sirve como factor pron&#xf3;stico independiente, sino que tambi&#xe9;n puede ayudar a orientar estrategias de tratamiento posoperatorio individualizadas y basadas en hip&#xf3;tesis. (AI-generated translation ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Haigui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Human Microbiome and Chronic Diseases at Sun Yat-sen University, Ministry of Education, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Jingrong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Jinlin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhenghua</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Peisi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Junyi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ziming</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Zixiao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Ze</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Yingguo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Mingzhe</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Tuoyang</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaoxia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaolin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Human Microbiome and Chronic Diseases at Sun Yat-sen University, Ministry of Education, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Huichuan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Human Microbiome and Chronic Diseases at Sun Yat-sen University, Ministry of Education, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Binbin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Jinxin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2089-7084</Identifier><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Yanxin</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-5200-3997</Identifier><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01211210</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>2023A04J1817, JL</GrantID><Agency>the Science and Technology Program of Guangzhou</Agency><Country/></Grant><Grant><GrantID>1010CG(2022)-02, MH</GrantID><Agency>the Sixth Affiliated Hospital of Sun Yat-sen University Clinical Research-'1010' Program</Agency><Country/></Grant><Grant><GrantID>A2023094, JL</GrantID><Agency>the Medical Scientific Research Foundation of Guangdong Province</Agency><Country/></Grant><Grant><GrantID>No. R2021217202512965, YL</GrantID><Agency>the Excellent Talent Training Project of the Sixth Affiliated Hospital of Sun Yat-sen University</Agency><Country/></Grant><Grant><GrantID>No. 2022JBGS07, YL</GrantID><Agency>the Scientific Research Project of the Sixth Affiliated Hospital of Sun Yat-sen University</Agency><Country/></Grant><Grant><GrantID>2022007, MH; 2025006&#xef;&#xbc;&#x152;YL</GrantID><Agency>the Fundamental Research Funds for the Central Universities, Sun Yat-sen University</Agency><Country/></Grant><Grant><GrantID>2020B1111170004</GrantID><Agency>the Program of Introducing Talents of Discipline to Universities, the Program of Guangdong Provincial Clinical Research Center for Digestive Diseases</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>Q573I9DVLP</RegistryNumber><NameOfSubstance UI="D002955">Leucovorin</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3P01618RT</RegistryNumber><NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009944">Organoplatinum Compounds</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C410216">Folfox protocol</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002955" MajorTopicYN="N">Leucovorin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009944" MajorTopicYN="N">Organoplatinum Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="N">Proctectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059186" MajorTopicYN="N">Chemoradiotherapy, Adjuvant</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008198" MajorTopicYN="Y">Lymph Nodes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FOWARC clinical trial</Keyword><Keyword MajorTopicYN="N">Locally advanced rectal cancer</Keyword><Keyword MajorTopicYN="N">Neoadjuvant therapy</Keyword><Keyword MajorTopicYN="N">Nodal status</Keyword><Keyword MajorTopicYN="N">Tumor downstaging</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>8</Day><Hour>12</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>8</Day><Hour>7</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40626521</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003846</ArticleId><ArticleId IdType="pii">00003453-990000000-00997</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Koukourakis IM, Kouloulias V, Tiniakos D, Georgakopoulos I, Zygogianni A. Current status of locally advanced rectal cancer therapy and future prospects. Crit Rev Oncol Hematol. 2023;186:103992.</Citation></Reference><Reference><Citation>Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229&#x2013;263.</Citation></Reference><Reference><Citation>Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12&#x2013;49.</Citation></Reference><Reference><Citation>Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:17&#x2013;48.</Citation></Reference><Reference><Citation>Zheng RS, Chen R, Han BF, et al. Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi. 2024;46:221&#x2013;231.</Citation></Reference><Reference><Citation>Wilkinson N. Management of rectal cancer. Surg Clin North Am. 2020;100:615&#x2013;628.</Citation></Reference><Reference><Citation>Benson AB, Venook AP, Adam M, et al. NCCN Guidelines&#xae; Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22:366&#x2013;375.</Citation></Reference><Reference><Citation>Chen P-J, Wang L, Sun T-T, . Total neoadjuvant treatment for MRI-stratified high-risk rectal cancer: a single-center, single-arm, prospective Phase II trial (PKUCH-R02). Gastroenterol Rep. 2023;11:goad017.</Citation></Reference><Reference><Citation>Knippen S, Hildebrandt G, Putz F, Goss&#xe9; LL, Ritz J-P, Duma M-N. Assessing the practice of total neoadjuvant therapy for rectal cancer: an online survey among radiation oncology departments in Germany and German-speaking regions of Austria and Switzerland. Clin Exp Med. 2024;24:242.</Citation></Reference><Reference><Citation>Viola Malet M; LATAM collaborative colorectal surgery consortium. Short-term surgical outcomes of rectal adenocarcinoma surgical treatment in Latin America: a multicenter, retrospective assessment in 49 centers from 12 countries. Int J Colorectal Dis. 2024;39:210.</Citation></Reference><Reference><Citation>Coraglio MF, Eleta MA, Kujaruk MR, et al. Analysis of long-term oncological results of clinical versus pathological responses after neoadjuvant treatment in locally advanced rectal cancer. World J Surg Oncol. 2020;18:313.</Citation></Reference><Reference><Citation>Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial. J Clin Oncol. 2016;34:3300&#x2013;3307.</Citation></Reference><Reference><Citation>Zhang J, Chi P, Shi L, . Neoadjuvant modified infusional fluorouracil, leucovorin, and oxaliplatin with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: updated results of the FOWARC study after a median follow-up of 10 years. J Clin Oncol. 2024;43:633&#x2013;640.</Citation></Reference><Reference><Citation>Li W-C, Zhao J-K, Feng W-Q, et al. Retrospective research of neoadjuvant therapy on tumor-downstaging, post-operative complications, and prognosis in locally advanced rectal cancer. World J Gastrointest Surg. 2021;13:267&#x2013;278.</Citation></Reference><Reference><Citation>Quah H-M, Chou JF, Gonen M, et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer. 2008;113:57&#x2013;64.</Citation></Reference><Reference><Citation>Park IJ, You YN, Agarwal A, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012;30:1770&#x2013;1776.</Citation></Reference><Reference><Citation>Kim NK, Baik SH, Seong JS, et al. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: impact of postirradiated pathologic downstaging on local recurrence and survival. Ann Surg. 2006;244:1024&#x2013;1030.</Citation></Reference><Reference><Citation>Haynes AB, You YN, Hu C-Y, et al. Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: analysis of Surveillance, Epidemiology, and End Results&#x2014;Medicare data, 1998-2007. Cancer. 2014;120:1162&#x2013;1170.</Citation></Reference><Reference><Citation>Wen B, Zhang L, Wang C, et al. Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy. Radiat Oncol. 2015;10:124.</Citation></Reference><Reference><Citation>Bipat S, Glas AS, Slors FJM, Zwinderman AH, Bossuyt PMM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging&#x2014;a meta-analysis. Radiology. 2004;232:773&#x2013;783.</Citation></Reference><Reference><Citation>Chen HT, Xu GQ, Teng XD, Chen YP, Chen LH, Li YM. Diagnostic accuracy of endoscopic ultrasonography for rectal neuroendocrine neoplasms. World J Gastroenterol. 2014;20:10470&#x2013;10477.</Citation></Reference><Reference><Citation>Attenberger UI, Pilz LR, Morelli JN, et al. Multi-parametric MRI of rectal cancer&#x2014;do quantitative functional MR measurements correlate with radiologic and pathologic tumor stages? Eur J Radiol. 2014;83:1036&#x2013;1043.</Citation></Reference><Reference><Citation>Nougaret S, Rouanet P, Molinari N, et al. MR volumetric measurement of low rectal cancer helps predict tumor response and outcome after combined chemotherapy and radiation therapy. Radiology. 2012;263:409&#x2013;418.</Citation></Reference><Reference><Citation>Giusti S, Buccianti P, Castagna M, et al. Preoperative rectal cancer staging with phased-array MR. Radiat Oncol. 2012;7:29.</Citation></Reference><Reference><Citation>Kim SH, Lee JM, Hong SH, et al. Locally advanced rectal cancer: added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy. Radiology. 2009;253:116&#x2013;125.</Citation></Reference><Reference><Citation>O&#x2019;Neill BDP, Salerno G, Thomas K, Tait DM, Brown G. MR vs CT imaging: low rectal cancer tumour delineation for three-dimensional conformal radiotherapy. Br J Radiol. 2009;82:509&#x2013;513.</Citation></Reference><Reference><Citation>O&#x2019;Neill BDP, Brown G, Heald RJ, Cunningham D, Tait DM. Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. Lancet Oncol. 2007;8:625&#x2013;633.</Citation></Reference><Reference><Citation>Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2009;74:673&#x2013;688.</Citation></Reference><Reference><Citation>Deng Y, Chi P, Lan P, et al. Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial. J Clin Oncol. 2019;37:3223&#x2013;3233.</Citation></Reference><Reference><Citation>Li X-T, Sun Y-S, Tang L, Cao K, Zhang X-Y. Evaluating local lymph node metastasis with magnetic resonance imaging, endoluminal ultrasound and computed tomography in rectal cancer: a meta-analysis. Colorectal Dis. 2015;17:O129&#x2013;O135.</Citation></Reference><Reference><Citation>Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012;23:2479&#x2013;2516.</Citation></Reference><Reference><Citation>Bosset JF, Calais G, Mineur L, et al.; EORTC Radiation Oncology Group. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15:184&#x2013;190.</Citation></Reference><Reference><Citation>Breugom AJ, Swets M, Bosset JF, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16:200&#x2013;207.</Citation></Reference><Reference><Citation>Glynne-Jones R, Counsell N, Quirke P, et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol. 2014;25:1356&#x2013;1362.</Citation></Reference><Reference><Citation>Verheij FS, Omer DM, Williams H, et al. Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial. J Clin Oncol. 2024;42:500&#x2013;506.</Citation></Reference><Reference><Citation>Dijkstra EA, Zwart WH, Nilsson PJ, et al.; collaborative investigators. The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer&#x2014;results from the RAPIDO trial. ESMO Open. 2023;8:101158.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39508482</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Rectal Cancer Watch-and-Wait Management: Experience of 545 Patients From the US Rectal Cancer Research Group.</ArticleTitle><Pagination><StartPage>180</StartPage><EndPage>189</EndPage><MedlinePgn>180-189</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003586</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The use of a watch-and-wait management strategy after a complete clinical response to neoadjuvant therapy for rectal cancer is increasing. However, insights into implementation, treatments, and outcomes on a national level in the United States are limited.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate and report on watch-and-wait management practices and outcomes in the United States.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Multicenter.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients with stage II or III rectal cancer who underwent intentional watch-and-wait management between January 2015 and August 2022.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Patient and tumor characteristics, neoadjuvant treatment and response, local cancer regrowth and metastasis, salvage surgery, overall survival, and disease-specific survival.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 545 patients from 33 centers, follow-up was 21 months (range, 9-37). Total neoadjuvant therapy or other types of neoadjuvant therapy were used in 395 (72%) and 150 (28%) patients, respectively. The estimated 3-year local regrowth rate was 23.8% (95% CI, 19.1%-29.4%). Patients with local regrowth had higher distant metastases incidence (14.2% vs 3.5%, p &lt; 0.001). Salvage surgery was performed in 74 of 84 patients (88%) with local regrowth and included rectal resection in 66 patients (89%) and local excision in 8 (11%). Of 64 salvage resections with known pathology results, 58 (91%) were margin-negative. Overall, 3-year overall survival was 94.8% (95% CI, 90.5%-97.2%) and 3-year disease-specific survival was 96.2% (95% CI, 91.8%-98.2%). Patients with and without local regrowth exhibited 3-year overall survival of 83.6% (95% CI, 68.4%-91.9%) and 97.7% (95% CI, 93.3%-99.2%), respectively.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Retrospective study.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This multicenter study indicates that the watch-and-wait approach for locally advanced rectal cancer is feasible with acceptable outcomes across a variety of geographical regions and practice settings in the United States. Local regrowth and distant metastasis rates were within published norms and salvage surgery proved effective. See Video Abstract .</AbstractText><AbstractText Label="MANEJO DE ESPERA Y OBSERVACIN DEL CNCER RECTAL EXPERIENCIA DE PACIENTES DEL GRUPO DE INVESTIGACIN DEL CNCER RECTAL DE EE UU" NlmCategory="UNASSIGNED">ANTECEDENTES:El uso de una estrategia de manejo de observaci&#xf3;n y espera despu&#xe9;s de una respuesta cl&#xed;nica completa a la terapia neoadyuvante para el c&#xe1;ncer de recto est&#xe1; aumentando. Sin embargo, los conocimientos sobre la implementaci&#xf3;n, los tratamientos y los resultados, a nivel nacional de los Estados Unidos, son limitados.OBJETIVO:Investigar e informar sobre las pr&#xe1;cticas y los resultados del manejo de observaci&#xf3;n y espera en los EE. UU.DISE&#xd1;O:Estudio retrospectivo.ESCENARIO:Multic&#xe9;ntrico.PACIENTES:Pacientes con c&#xe1;ncer de recto en estadio II o III que se sometieron a un manejo de observaci&#xf3;n y espera intencional entre enero de 2015 y agosto de 2022.PRINCIPALES MEDIDAS DE RESULTADOS:Caracter&#xed;sticas del paciente y del tumor, tratamiento neoadyuvante y respuesta, recrecimiento local del c&#xe1;ncer y met&#xe1;stasis, cirug&#xed;a de rescate, supervivencia general y espec&#xed;fica de la enfermedad.RESULTADOS:Entre 545 pacientes de 33 centros, el seguimiento fue de 21 meses (rango, 9-37). Se utiliz&#xf3; terapia neoadyuvante total u otros tipos de neoadyuvancia en 395 (72%) y 150 (28%) de los pacientes, respectivamente. La tasa estimada de recrecimiento local a 3 a&#xf1;os fue del 23,8% (IC del 95%: 19,1-29,4%). Los pacientes con recrecimiento local tuvieron una mayor incidencia de met&#xe1;stasis a distancia (14,2% frente a 3,5%, p &lt; 0,001). Se realiz&#xf3; cirug&#xed;a de rescate en 74/84 (88%) pacientes con recrecimiento local e incluy&#xf3; resecci&#xf3;n rectal en 66 (89%) y escisi&#xf3;n local en 8 (11%). De 64 resecciones de rescate con resultados patol&#xf3;gicos conocidos, 58 (91%) fueron m&#xe1;rgenes negativos. En general, la supervivencia global a los 3 a&#xf1;os fue del 94,8 % (IC del 95 %: 90,5-97,2 %) y la supervivencia espec&#xed;fica de la enfermedad a los 3 a&#xf1;os del 96,2 % (IC del 95 %: 91,8-98,2 %). Los pacientes con y sin recrecimiento local mostraron una supervivencia global a los 3 a&#xf1;os del 83,6 % (IC del 95 %: 68,4-91,9 %) y del 97,7 % (IC del 95 %: 93,3-99,2 %), respectivamente.LIMITACIONES:Estudio retrospectivo.CONCLUSI&#xd3;N:Este estudio multic&#xe9;ntrico indica que el enfoque de observaci&#xf3;n y espera para el c&#xe1;ncer rectal localmente avanzado es factible con resultados aceptables en una variedad de regiones geogr&#xe1;ficas y entornos de pr&#xe1;ctica en los EE. UU. Las tasas de recrecimiento local y met&#xe1;stasis a distancia estuvieron dentro de las normas publicadas y la cirug&#xed;a de rescate result&#xf3; eficaz. (Traducci&#xf3;n-Dr Yolanda Colorado ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Samuel H</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0003-0187-4255</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Widmar</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monson</LastName><ForeName>John R T</ForeName><Initials>JRT</Initials><AffiliationInfo><Affiliation>Northwell Health, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleming</LastName><ForeName>Fergal J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Rochester Medical Center, Rochester, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Arden M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Surgery, Stanford University, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Jon D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>US Rectal Cancer Research Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057832" MajorTopicYN="Y">Watchful Waiting</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016879" MajorTopicYN="N">Salvage Therapy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="ANTECEDENTES:">El uso de una estrategia de manejo de observaci&#xf3;n y espera despu&#xe9;s de una respuesta cl&#xed;nica completa a la terapia neoadyuvante para el c&#xe1;ncer de recto est&#xe1; aumentando. Sin embargo, los conocimientos sobre la implementaci&#xf3;n, los tratamientos y los resultados, a nivel nacional de los Estados Unidos, son limitados.</AbstractText><AbstractText Label="OBJETIVO:">Investigar e informar sobre las pr&#xe1;cticas y los resultados del manejo de observaci&#xf3;n y espera en los EE. UU.</AbstractText><AbstractText Label="DISE&#xd1;O:">Estudio retrospectivo.</AbstractText><AbstractText Label="ESCENARIO:">Multic&#xe9;ntrico.</AbstractText><AbstractText Label="PACIENTES:">Pacientes con c&#xe1;ncer de recto en estadio II o III que se sometieron a un manejo de observaci&#xf3;n y espera intencional entre enero de 2015 y agosto de 2022.</AbstractText><AbstractText Label="PRINCIPALES MEDIDAS DE RESULTADOS:">Caracter&#xed;sticas del paciente y del tumor, tratamiento neoadyuvante y respuesta, recrecimiento local del c&#xe1;ncer y met&#xe1;stasis, cirug&#xed;a de rescate, supervivencia general y espec&#xed;fica de la enfermedad.</AbstractText><AbstractText Label="RESULTADOS:">Entre 545 pacientes de 33 centros, el seguimiento fue de 21 meses (rango, 9&#x2013;37). Se utiliz&#xf3; terapia neoadyuvante total u otros tipos de neoadyuvancia en 395 (72%) y 150 (28%) de los pacientes, respectivamente. La tasa estimada de recrecimiento local a 3 a&#xf1;os fue del 23,8% (IC del 95%: 19,1&#x2013;29,4%). Los pacientes con recrecimiento local tuvieron una mayor incidencia de met&#xe1;stasis a distancia (14,2% frente a 3,5%, p &lt; 0,001). Se realiz&#xf3; cirug&#xed;a de rescate en 74/84 (88%) pacientes con recrecimiento local e incluy&#xf3; resecci&#xf3;n rectal en 66 (89%) y escisi&#xf3;n local en 8 (11%). De 64 resecciones de rescate con resultados patol&#xf3;gicos conocidos, 58 (91%) fueron m&#xe1;rgenes negativos. En general, la supervivencia global a los 3 a&#xf1;os fue del 94,8 % (IC del 95 %: 90,5&#x2013;97,2 %) y la supervivencia espec&#xed;fica de la enfermedad a los 3 a&#xf1;os del 96,2 % (IC del 95 %: 91,8&#x2013;98,2 %). Los pacientes con y sin recrecimiento local mostraron una supervivencia global a los 3 a&#xf1;os del 83,6 % (IC del 95 %: 68,4&#x2013;91,9 %) y del 97,7 % (IC del 95 %: 93,3&#x2013;99,2 %), respectivamente.</AbstractText><AbstractText Label="LIMITACIONES:">Estudio retrospectivo.</AbstractText><AbstractText Label="CONCLUSI&#xd3;N:">Este estudio multic&#xe9;ntrico indica que el enfoque de observaci&#xf3;n y espera para el c&#xe1;ncer rectal localmente avanzado es factible con resultados aceptables en una variedad de regiones geogr&#xe1;ficas y entornos de pr&#xe1;ctica en los EE. UU. Las tasas de recrecimiento local y met&#xe1;stasis a distancia estuvieron dentro de las normas publicadas y la cirug&#xed;a de rescate result&#xf3; eficaz. <i>(Pre-proofed version)</i></AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></OtherAbstract><InvestigatorList><Investigator ValidYN="Y"><LastName>Gupta</LastName><ForeName>Abhinav</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Price</LastName><ForeName>Adam D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Booth</LastName><ForeName>Adam L</ForeName><Initials>AL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flores</LastName><ForeName>Aileen De Mucha</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khan</LastName><ForeName>Aimal</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fichera</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hawkins</LastName><ForeName>Alexander T</ForeName><Initials>AT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayman</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fa</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuhnen</LastName><ForeName>Angela H</ForeName><Initials>AH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Melio</LastName><ForeName>Anna A</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fabrizio</LastName><ForeName>Anne C</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loria</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villano</LastName><ForeName>Anthony M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caycedo-Marulanda</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>Arden</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amir</LastName><ForeName>Arslan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duby</LastName><ForeName>Ashley</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shogan</LastName><ForeName>Benjamin D</ForeName><Initials>BD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosamond</LastName><ForeName>Brendan</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Brian N</ForeName><Initials>BN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monahan</LastName><ForeName>Brian V</ForeName><Initials>BV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Newton</LastName><ForeName>Carla</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hong</LastName><ForeName>Christine L</ForeName><Initials>CL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aquina</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munroe</LastName><ForeName>Cody</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donahue</LastName><ForeName>Colleen A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayden</LastName><ForeName>Dana M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kleiman</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>David D Q</ForeName><Initials>DDQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dietz</LastName><ForeName>David W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keller</LastName><ForeName>Deborah S</ForeName><Initials>DS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baker</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strungs</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flemming</LastName><ForeName>Fergal</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Romero-Hernandez</LastName><ForeName>Fernanda</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saidi</LastName><ForeName>Hela</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Govekar</LastName><ForeName>Henry R</ForeName><Initials>HR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paquette</LastName><ForeName>Ian M</ForeName><Initials>IM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klausner</LastName><ForeName>Jake</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Jeanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farma</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaplan</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller-Ocuin</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rytych</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knight</LastName><ForeName>Jimmie</ForeName><Initials>J</Initials><Suffix>3rd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Marks M D</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monson</LastName><ForeName>John R T</ForeName><Initials>JRT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vogel</LastName><ForeName>Jon</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abelson</LastName><ForeName>Jonathan S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kohn</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saraidaridis</LastName><ForeName>Julia T</ForeName><Initials>JT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wells</LastName><ForeName>Katerina K O</ForeName><Initials>KKO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akemi Tavares</LastName><ForeName>Kelli Beth</ForeName><Initials>KB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cologne</LastName><ForeName>Kyle G</ForeName><Initials>KG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Temple</LastName><ForeName>Larissa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bustamente-Lopez</LastName><ForeName>Leo</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Armstrong</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Force</LastName><ForeName>Luanne</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varma</LastName><ForeName>Madhulika G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrara</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Widmar</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whiteford</LastName><ForeName>Mark H</ForeName><Initials>MH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kalady</LastName><ForeName>Matthew F</ForeName><Initials>MF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hill</LastName><ForeName>Maureen</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chang</LastName><ForeName>Melissa I</ForeName><Initials>MI</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGee</LastName><ForeName>Michael F</ForeName><Initials>MF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matos</LastName><ForeName>Monique C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>Piyush</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aoun</LastName><ForeName>Rami James N</ForeName><Initials>RJN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daugherty</LastName><ForeName>Ray S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cleary</LastName><ForeName>Robert K</ForeName><Initials>RK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guevara</LastName><ForeName>Salvador G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Younan</LastName><ForeName>Samuel A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lai</LastName><ForeName>Samuel H</ForeName><Initials>SH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boatman</LastName><ForeName>Sonja</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greco</LastName><ForeName>Stephanie H</ForeName><Initials>SH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Russell</LastName><ForeName>Tara A</ForeName><Initials>TA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prasad Poola</LastName><ForeName>Taylor Penn V</ForeName><Initials>TPV</Initials></Investigator><Investigator ValidYN="Y"><LastName>George</LastName><ForeName>Virgilio V</ForeName><Initials>VV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poylin</LastName><ForeName>Vitaliy Y</ForeName><Initials>VY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simianu</LastName><ForeName>Vlad V</ForeName><Initials>VV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gaertner</LastName><ForeName>Wolfgang B</ForeName><Initials>WB</Initials></Investigator><Investigator ValidYN="Y"><LastName>To</LastName><ForeName>Yue-Yun</ForeName><Initials>YY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sun</LastName><ForeName>Zhifei</ForeName><Initials>Z</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>24</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>13</Day><Hour>13</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>7</Day><Hour>8</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39508482</ArticleId><ArticleId IdType="mid">NIHMS2083505</ArticleId><ArticleId IdType="pmc">PMC12232607</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003586</ArticleId><ArticleId IdType="pii">00003453-990000000-00789</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:1139&#x2013;1167.</Citation><ArticleIdList><ArticleId IdType="pubmed">36240850</ArticleId></ArticleIdList></Reference><Reference><Citation>Habr-Gama A, de Souza PM, Ribeiro U Jr, et al. Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum. 1998;41:1087&#x2013;1096.</Citation><ArticleIdList><ArticleId IdType="pubmed">9749491</ArticleId></ArticleIdList></Reference><Reference><Citation>Habr-Gama A, Oliva Perez R, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1356472</ArticleId><ArticleId IdType="pubmed">15383798</ArticleId></ArticleIdList></Reference><Reference><Citation>Langenfeld SJ, Davis BR, Vogel JD, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of rectal cancer 2023 supplement. Dis Colon Rectum. 2024;67:18&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">37647138</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Valk MJM, Hilling DE, Bastiaannet E, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch &amp; Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391:2537&#x2013;2545.</Citation><ArticleIdList><ArticleId IdType="pubmed">29976470</ArticleId></ArticleIdList></Reference><Reference><Citation>Chadi SA, Malcomson L, Ensor J, et al. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2018;3:825&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pubmed">30318451</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin RI, Schiff JP, Shetty AS, et al. Circumferential resection margin as predictor of nonclinical complete response in nonoperative management of rectal cancer. Dis Colon Rectum. 2023;66:973&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">36876988</ArticleId></ArticleIdList></Reference><Reference><Citation>Dattani M, Heald RJ, Goussous G, et al. Oncological and survival outcomes in watch and wait patients with a clinical complete response after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and pooled analysis. Ann Surg. 2018;268:955&#x2013;967.</Citation><ArticleIdList><ArticleId IdType="pubmed">29746338</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40:2546&#x2013;2556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9362876</ArticleId><ArticleId IdType="pubmed">35483010</ArticleId></ArticleIdList></Reference><Reference><Citation>Habr-Gama A, S&#xe3;o Juli&#xe3;o GP, Fernandez LM, et al. Achieving a complete clinical response after neoadjuvant chemoradiation that does not require surgical resection: it may take longer than you think! Dis Colon Rectum. 2019;62:802&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">31188180</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez-Rodriguez RM, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal cancer treated with total neoadjuvant therapy. Dis Colon Rectum. 2021;64:1463&#x2013;1470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8820240</ArticleId><ArticleId IdType="pubmed">34508014</ArticleId></ArticleIdList></Reference><Reference><Citation>Rettig RL, Beard BW, Ryoo JJ, et al. Total neoadjuvant therapy significantly increases complete clinical response. Dis Colon Rectum. 2023;66:374&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">35239525</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez LM, S&#xe3;o Juli&#xe3;o GP, Figueiredo NL, et al. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch &amp; Wait Database: a retrospective, international, multicentre registry study. Lancet Oncol. 2021;22:43&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">33316218</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith JJ, Strombom P, Chow OS, et al. Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol. 2019;5:e185896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6459120</ArticleId><ArticleId IdType="pubmed">30629084</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez LM, S&#xe3;o Juli&#xe3;o GP, Renehan AG, et al. The risk of distant metastases in patients with clinical complete response managed by watch and wait after neoadjuvant therapy for rectal cancer: the influence of local regrowth in the International Watch and Wait Database. Dis Colon Rectum. 2023;66:41&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">36515514</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700030</ArticleId><ArticleId IdType="pubmed">18929686</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman BC, Lai SH, Friedrich T, et al. Rectal cancer: clinical and molecular predictors of a complete response to total neoadjuvant therapy. Dis Colon Rectum. 2023;66:521&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">34984995</ArticleId></ArticleIdList></Reference><Reference><Citation>Loria A, Tejani MA, Temple LK, et al. Practice patterns for organ preservation in US patients with rectal cancer, 2006&#x2013;2020. JAMA Oncol. 2024;10:79&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10636650</ArticleId><ArticleId IdType="pubmed">37943566</ArticleId></ArticleIdList></Reference><Reference><Citation>Sammour T, Price BA, Krause KJ, Chang GJ. Nonoperative management or &#x2018;watch and wait&#x2019; for rectal cancer with complete clinical response after neoadjuvant chemoradiotherapy: a critical appraisal. Ann Surg Oncol. 2017;24:1904&#x2013;1915.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6106774</ArticleId><ArticleId IdType="pubmed">28324284</ArticleId></ArticleIdList></Reference><Reference><Citation>Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:501&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pubmed">28479372</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai S, Widmar M, Monson J, Morris A, Fleming F, Vogel J. Rectal cancer watch &amp; wait strategy: the U.S. Rectal Cancer Research Group experience with 545 patients [ASCRS abstract T103]. Dis Colon Rectum. 2024;67:e504&#x2013;e505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12232607</ArticleId><ArticleId IdType="pubmed">39508482</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38498775</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Rectal Cancer Survival for Residual Carcinoma In Situ Versus Pathologic Complete Response After Neoadjuvant Therapy.</ArticleTitle><Pagination><StartPage>920</StartPage><EndPage>928</EndPage><MedlinePgn>920-928</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003261</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pathologic complete response after neoadjuvant chemoradiotherapy for rectal cancer is associated with improved survival. It is unclear whether residual carcinoma in situ portends a similar outcome.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare the survival of patients with locally advanced rectal cancer who received neoadjuvant therapy and achieved pathologic carcinoma in situ versus pathologic complete response.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">National public database.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">A total of 4594 patients in the National Cancer Database from 2006 to 2016 with locally advanced rectal cancer who received neoadjuvant therapy, underwent surgery, and had node-negative ypTis or ypT0 on final pathology were included. Of these, 4321 patients (94.1%) had ypT0 and 273 (5.9%) had ypTis on final pathology.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Overall survival.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median age was 60 years, and 1822 patients (39.7%) were women. On initial staging, 54.5% (n&#x2009;=&#x2009;2503) had stage II disease and 45.5% (n&#x2009;=&#x2009;2091) had stage III disease. The ypTis group had decreased overall survival compared to the ypT0 group (HR 1.42; 95% CI, 1.04-1.95; p &#x2009;=&#x2009;0.028). Other factors associated with decreased overall survival were older age at diagnosis, increasing Charlson-Deyo score, and poorly differentiated tumor grade. Variables associated with improved survival were female sex, private insurance, and receipt of both neoadjuvant and adjuvant chemotherapy. For the total cohort, there was no difference in survival between clinical stage II and stage III.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Standard therapy versus total neoadjuvant therapy could not be abstracted. Overall survival was defined as the time from surgery to death from any cause or last contact, allowing for some erroneously misclassified deaths.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ypTis is associated with worse overall survival than ypT0 for patients with locally advanced rectal cancer who receive neoadjuvant chemoradiotherapy followed by surgery. For this cohort, clinical stage was not a significant predictor of survival. Prospective trials comparing survival for these pathologic outcomes are needed. See Video Abstract .</AbstractText><AbstractText Label="SUPERVIVENCIA DEL CNCER DE RECTO PARA EL CARCINOMA RESIDUAL IN SITU VS RESPUESTA PATOLGICA COMPLETA DESPUS DE LA TERAPIA NEOADYUVANTE" NlmCategory="UNASSIGNED">ANTECEDENTESLa respuesta patol&#xf3;gica completa despu&#xe9;s de la quimiorradioterapia neoadyuvante para el c&#xe1;ncer de recto se asocia con una mayor supervivencia. No est&#xe1; claro si el carcinoma residual in situ presagia un resultado similar.OBJETIVOComparar la supervivencia de pacientes con c&#xe1;ncer de recto localmente avanzado que recibieron terapia neoadyuvante y lograron un carcinoma patol&#xf3;gico in situ versus una respuesta patol&#xf3;gica completa.DISE&#xd1;OEstudio de cohorte retrospectivo.ESCENARIOBase de datos p&#xfa;blica nacional.PACIENTESSe incluyeron 4,594 pacientes de la Base de Datos Nacional de C&#xe1;ncer de 2006 a 2016 con c&#xe1;ncer de recto localmente avanzado que recibieron terapia neoadyuvante, fueron sometidos a cirug&#xed;a y tuvieron ganglios negativos, ypTis o ypT0 en el reporte patol&#xf3;gico final. 4.321 (94,1%) tuvieron ypT0 y 273 (5,9%) tuvieron ypTis en el reporte final.PRINCIPALES MEDIDAS DE RESULTADOSupervivencia general.RESULTADOSLa mediana de edad fue de 60 a&#xf1;os. 1.822 pacientes (39,7%) fueron mujeres. El 54,5% (n = 2.503) tuvo la enfermedad en estadio II y el 45,5% (n = 2.091) tuvo la enfermedad en estadio III seg&#xfa;n la estadificaci&#xf3;n inicial. El grupo ypTis tuvo una supervivencia general reducida en comparaci&#xf3;n con el grupo ypT0 (HR 1,42, IC 95 % 1,04-1,95, p = 0,028). Otros factores asociados con una menor supervivencia general fueron una edad m&#xe1;s avanzada al momento del diagn&#xf3;stico, un aumento de la puntuaci&#xf3;n de Charlson-Deyo y un grado tumoral poco diferenciado. Las variables asociadas con una mejor supervivencia fueron el sexo femenino, el seguro privado y la recepci&#xf3;n de quimioterapia neoadyuvante y adyuvante. Para la cohorte total, no hubo diferencias en la supervivencia entre el estadio cl&#xed;nico 2 y el estadio 3.LIMITACIONESNo se pudo resumir el tratamiento est&#xe1;ndar versus el tratamiento neoadyuvante total. La supervivencia general se defini&#xf3; como el tiempo transcurrido desde la cirug&#xed;a hasta la muerte por cualquier causa o &#xfa;ltimo contacto, lo que permite algunas muertes err&#xf3;neamente clasificadas.CONCLUSIONESypTis se asocia con una peor supervivencia general que ypT0 en pacientes con c&#xe1;ncer de recto localmente avanzado que reciben quimiorradioterapia neoadyuvante seguida de cirug&#xed;a. Para esta cohorte, el estadio cl&#xed;nico no fue un predictor significativo de supervivencia. Se necesitan ensayos prospectivos que comparen la supervivencia de estos resultados patol&#xf3;gicos. ( Traducci&#xf3;n-Dr Osvaldo Gauto ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kohrman</LastName><ForeName>Nathan M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>University of Southern California Keck School of Medicine, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wlodarczyk</LastName><ForeName>Jordan R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Southern California Keck School of Medicine, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Population and Public Health Sciences, University of Southern California Keck School of Medicine, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McAndrew</LastName><ForeName>Nicholas P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Algaze</LastName><ForeName>Sandra D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, University of Southern California Keck School of Medicine, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cologne</LastName><ForeName>Kyle G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, University of Southern California Keck School of Medicine, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sang W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, University of Southern California Keck School of Medicine, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koller</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, University of Southern California Keck School of Medicine, Los Angeles, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="Y">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018365" MajorTopicYN="Y">Neoplasm, Residual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="N">Proctectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000095384" MajorTopicYN="N">Pathologic Complete Response</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>13</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>19</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>18</Day><Hour>15</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38498775</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003261</ArticleId><ArticleId IdType="pii">00003453-202407000-00010</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel R, Sandeep Wagle N, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:233&#x2013;254.</Citation></Reference><Reference><Citation>Ludmir EB, Palta M, Willett CG, Czito BG. Total neoadjuvant therapy for rectal cancer: an emerging option. Cancer. 2017;123:1497&#x2013;1506.</Citation></Reference><Reference><Citation>Iv AA, Koprowski MA, Nabavizadeh N, Tsikitis VL. The evolution of rectal cancer treatment: the journey to total neoadjuvant therapy and organ preservation. Ann Gastroenterol. 2022;35:226&#x2013;233.</Citation></Reference><Reference><Citation>National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology (NCCN Guidelines&#xae;) for Rectal Cancer V.3.2023. National Comprehensive Cancer Network, Inc. 2023. https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf . Accessed June 1, 2023.</Citation></Reference><Reference><Citation>Bahadoer RR, Dijkstra EA, van Etten B, et al.; RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29&#x2013;42.</Citation></Reference><Reference><Citation>Garcia-Aguilar J, Chow OS, Smith DD, et al.; Timing of Rectal Cancer Response to Chemoradiation Consortium. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16:957&#x2013;966.</Citation></Reference><Reference><Citation>Conroy T, Bosset J-F, Etienne P-L, et al.; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702&#x2013;715.</Citation></Reference><Reference><Citation>Jin J, Tang Y, Hu C, et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol. 2022;40:1681&#x2013;1692.</Citation></Reference><Reference><Citation>Liu S, Jiang T, Xiao L, et al. Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis. Oncologist. 2021;26:e1555&#x2013;e1566.</Citation></Reference><Reference><Citation>Yeo SG, Kim DY, Kim TH, et al. Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01). Ann Surg. 2010;252:998&#x2013;1004.</Citation></Reference><Reference><Citation>Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835&#x2013;844.</Citation></Reference><Reference><Citation>Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29:4633&#x2013;4640.</Citation></Reference><Reference><Citation>Shin JK, Huh JW, Lee WY, et al. Clinical prediction model of pathological response following neoadjuvant chemoradiotherapy for rectal cancer. Sci Rep. 2022;12:7145.</Citation></Reference><Reference><Citation>O&#x2019;Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;32:1927&#x2013;1934.</Citation></Reference><Reference><Citation>Fokas E, Schlenska-Lange A, Polat B, et al.; German Rectal Cancer Study Group. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO/AIO-12 randomized clinical trial. JAMA Oncol. 2022;8:e215445.</Citation></Reference><Reference><Citation>Dellas K, H&#xf6;hler T, Reese T, et al. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. Radiat Oncol. 2013;8:90.</Citation></Reference><Reference><Citation>Fernandez-Martos C, Garcia-Albeniz X, Pericay C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial&#x2020;. Ann Oncol. 2015;26:1722&#x2013;1728.</Citation></Reference><Reference><Citation>Bujko K, Wyrwicz L, Rutkowski A, et al.; Polish Colorectal Study Group. Long-course oxaliplatin-based preoperative chemoradiation versus 5&#x2009;&#xd7;&#x2009;5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016;27:834&#x2013;842.</Citation></Reference><Reference><Citation>Cercek A, Roxburgh CSD, Strombom P, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 2018;4:e180071.</Citation></Reference><Reference><Citation>Quah HM, Chou JF, Gonen M, et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer. 2008;113:57&#x2013;64.</Citation></Reference><Reference><Citation>Voss RK, Lin JC, Roper MT, et al. Adjuvant chemotherapy does not improve recurrence-free survival in patients with stage 2 or stage 3 rectal cancer after neoadjuvant chemoradiotherapy and total mesorectal excision. Dis Colon Rectum. 2020;63:427&#x2013;440.</Citation></Reference><Reference><Citation>Paulson EC, Wirtalla C, Armstrong K, Mahmoud NN. Gender influences treatment and survival in colorectal cancer surgery. Dis Colon Rectum. 2009;52:1982&#x2013;1991.</Citation></Reference><Reference><Citation>Shahab D, Gabriel E, Attwood K, et al. Adjuvant chemotherapy is associated with improved overall survival in locally advanced rectal cancer after achievement of a pathologic complete response to chemoradiation. Clin Colorectal Cancer. 2017;16:300&#x2013;307.</Citation></Reference><Reference><Citation>Freischlag K, Sun Z, Adam MA, et al. Association between incomplete neoadjuvant radiotherapy and survival for patients with locally advanced rectal cancer. JAMA Surg. 2017;152:558&#x2013;564.</Citation></Reference><Reference><Citation>Robbins AS, Chen AY, Stewart AK, Staley CA, Virgo KS, Ward EM. Insurance status and survival disparities among nonelderly rectal cancer patients in the National Cancer Data Base. Cancer. 2010;116:4178&#x2013;4186.</Citation></Reference><Reference><Citation>Kozak KR, Moody JS. The impact of T and N stage on long-term survival of rectal cancer patients in the community. J Surg Oncol. 2008;98:161&#x2013;166.</Citation></Reference><Reference><Citation>Guillem JG, Chessin DB, Cohen AM, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005;241:829&#x2013;836.</Citation></Reference><Reference><Citation>Vecchio FM, Valentini V, Minsky BD, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys. 2005;62:752&#x2013;76017.</Citation></Reference><Reference><Citation>American Joint Committee on Cancer. Edge SB, Fritz AG, Byrd DR, Greene FL, Compton CC, Trotti III A eds. AJCC Cancer Staging Manual. 8th ed. Chicago, IL: American College of Surgeons; 2017.</Citation></Reference><Reference><Citation>Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40:2546&#x2013;2556.</Citation></Reference><Reference><Citation>Adamo M, Groves C, Dickie L, Ruhl J. SEER Program Coding and Staging Manual 2021. Bethesda, MD: National Cancer Institute; 2020.</Citation></Reference><Reference><Citation>George TJ, Allegra CJ, Yothers G. Neoadjuvant rectal (NAR) score: a new surrogate endpoint in rectal cancer clinical trials. Curr Colorectal Cancer Rep. 2015;11:275&#x2013;280.</Citation></Reference><Reference><Citation>Kim SH, Chang HJ, Kim DY, et al. What is the ideal tumor regression grading system in rectal cancer patients after preoperative chemoradiotherapy? Cancer Res Treat. 2016;48:998&#x2013;1009.</Citation></Reference><Reference><Citation>Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997;12(1):19&#x2013;23.</Citation></Reference><Reference><Citation>Mace AG, Pai RK, Stocchi L, Kalady MF. American Joint Committee on Cancer and College of American Pathologists regression grade: a new prognostic factor in rectal cancer. Dis Colon Rectum. 2015;58:32&#x2013;44.</Citation></Reference><Reference><Citation>Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164&#x2013;172.</Citation></Reference><Reference><Citation>Britten K, McAndrew N. Pathologic complete response as a surrogate endpoint in breast cancer. touchReviews Oncol Haematol. 2021;17:12&#x2013;17.</Citation></Reference><Reference><Citation>Mazouni C, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007;25:2650&#x2013;2655.</Citation></Reference><Reference><Citation>Zhao Q, Rashid A, Gong Y, et al. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol. 2012;16:29&#x2013;37.</Citation></Reference><Reference><Citation>Chatterjee D, Katz MH, Foo WC, et al. Prognostic significance of new AJCC tumor stage in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy. Am J Surg Pathol. 2017;41:1097&#x2013;1104.</Citation></Reference><Reference><Citation>van Hagen P, Hulshof MC, van Lanschot JJ, et al.; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074&#x2013;2084.</Citation></Reference><Reference><Citation>Conroy T, Etienne P-L, Rio E, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial. J Clin Oncol. 2023;41(suppl):LBA3504&#x2013;LBA3504.</Citation></Reference><Reference><Citation>Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:1139&#x2013;1167.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38319717</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Innate Immunity Activation in Newly Diagnosed Ileocolonic Crohn's Disease: A Cohort Study.</ArticleTitle><Pagination><StartPage>681</StartPage><EndPage>692</EndPage><MedlinePgn>681-692</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003145</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent studies showed that early surgery for Crohn's disease leads to a lower recurrence rate. However, the underlying mechanism is unknown.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The study aims to analyze the innate immunity microenvironment in ileal mucosa according to the duration of Crohn's disease.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A prospective cohort study.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Tertiary referral center for IBD surgery.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">A total of 88 consecutive patients with Crohn's disease undergoing ileocolonic resection were prospectively enrolled. Mucosal samples were obtained from both healthy and inflamed ileum. Data from a public data set were analyzed as an external validation cohort.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Neutrophil infiltration was evaluated by histological asessment and macrophage subpopulation was assessed by immunohistochemistry. Expressions of TLR2 , TLR4 , TLR5 , DEFB1 , DEFB4A , DEFB103 , DEFA5 , and DEFA6 were quantified by real-time quantitative polymerase chain reaction. Concentrations of BDNF, CCL-11, ICAM-1, IL-1A, IL-1&#x3b2;, IL-1RN, IL-12p40, IL-12p70, IL-15, IL-17A, IL-23A, MMP-3, CCL-3, KITLG, and VEGFA were determined with an immunometric assay.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Neutrophil infiltration is inversely correlated with disease duration. DEFB4A mRNA expression tended to be higher in late-stage Crohn's disease ( p = 0.07). A higher number of macrophages expressed CD163 at low intensity in late-stage Crohn's disease ( p = 0.04). The concentration of IL-15 ( p = 0.02) and IL-23A ( p = 0.05) was higher in healthy ileal mucosa of early-stage patients. In the external cohort, expressions of DEFB1 ( p = 0.03), DEFB4A ( p = 0.01), IL-2 ( p = 0.04), and IL-3 ( p = 0.03) increased in patients with late-stage Crohn's disease.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">A relatively small number of patients, especially in the newly diagnosed group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In newly diagnosed Crohn's disease, high levels of IL-15 and IL-23 in healthy mucosa suggest that innate immunity is the starter of acute inflammation. Moreover, M2 macrophages increase in the healthy mucosa of patients with late-stage Crohn's disease, suggesting that reparative and profibrotic processes are predominant in the long term, and in this phase, anti-inflammatory therapy may be less efficient. See Video Abstract .</AbstractText><AbstractText Label="ACTIVACIN DE LA INMUNIDAD INNATA EN LA RECIENTEMENTE DIAGNOSTICADA ENFERMEDAD DE CROHN ILEOCLICA UN ESTUDIO DE COHORTE" NlmCategory="UNASSIGNED">ANTECEDENTES:Estudios recientes demostraron que la cirug&#xed;a temprana para la enfermedad de Crohn (EC) conduce a una menor tasa de recurrencia. Sin embargo, se desconoce el mecanismo subyacente.OBJETIVO:El estudio tiene como objetivo analizar el microambiente de la inmunidad innata en la mucosa ileal seg&#xfa;n la duraci&#xf3;n de la EC.DISE&#xd1;O:Un estudio de cohorte prospectivo.AJUSTES:Centro terciario de referencia para cirug&#xed;a de EII.PACIENTES:Fueron registrados de manera prospectiva y consecutiva 88 pacientes con EC sometidos a resecci&#xf3;n ileocol&#xf3;nica. Se obtuvieron muestras de mucosa ileal, tanto del &#xed;leon sano como del &#xed;leon inflamado. Los datos se analizaron como una cohorte de validaci&#xf3;n externa.PRINCIPALES MEDIDAS DE RESULTADO:Fueron evaluados la infiltraci&#xf3;n de neutr&#xf3;filos por histolog&#xed;a y la subpoblaci&#xf3;n de macr&#xf3;fagos por inmunohistoqu&#xed;mica. La expresi&#xf3;n de TLR2, TLR4, TLR5, DEFB1, DEFB4A, DEFB103, DEFA5 y DEFA6 fueron cuantificados mediante qPCR en tiempo real. Las concentraciones de BDNF, CCL-11, ICAM-1, IL-1A, IL-1B, IL-1RN, IL-12 p40, IL-12 p70, IL-15, IL-17A, IL-23A, MMP-3, CCL-3, KITLG, VEGFA se determinaron con ensayo inmunom&#xe9;trico.RESULTADOS:La infiltraci&#xf3;n de neutr&#xf3;filos se correlaciona inversamente con la duraci&#xf3;n de la enfermedad. La expresi&#xf3;n del ARNm de DEFB4A mostro una tendencia a ser mayor en la EC en etapa tard&#xed;a ( p = 0,07). Un mayor n&#xfa;mero de macr&#xf3;fagos expresaron CD163 a baja intensidad en la etapa tard&#xed;a ( p = 0,04). La concentraci&#xf3;n de IL15 ( p = 0,02) e IL23A ( p = 0,05) fue mayor en la mucosa ileal sana de pacientes en estadio temprano. En la cohorte externa, la expresi&#xf3;n de DEFB1 ( p = 0,03) y DEFB4A ( p = 0,01), IL2 ( p = 0,04) e IL3 ( p = 0,03) aument&#xf3; en pacientes en etapa tard&#xed;a.LIMITACIONES:Un n&#xfa;mero relativamente peque&#xf1;o de pacientes, especialmente en el grupo reci&#xe9;n diagnosticado.CONCLUSIONES:En la EC reci&#xe9;n diagnosticada, los altos niveles de IL-15 e IL-23 en la mucosa sana sugieren que la inmunidad innata es el promotor de la inflamaci&#xf3;n aguda. Adem&#xe1;s, los macr&#xf3;fagos M2 aumentan en la mucosa sana de pacientes con EC en etapa tard&#xed;a, lo que sugiere que los procesos reparadores y profibr&#xf3;ticos son predominantes a largo plazo y en esta fase, la terapia antiinflamatoria puede ser menos eficiente. (Traducci&#xf3;n-Dr. Osvaldo Gauto ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Angriman</LastName><ForeName>Imerio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>General Surgery Unit 3, Azienda Ospedaliera di Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bordignon</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>General Surgery Unit 3, Azienda Ospedaliera di Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotsafti</LastName><ForeName>Andromachi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Advanced Translational Research, Veneto Institute of Oncology IOV, IRCCS, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mescoli</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pathology Unit, Department of Medicine (DIMED), University of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scarpa</LastName><ForeName>Melania</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pathology Unit, Department of Medicine (DIMED), University of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruffolo</LastName><ForeName>Cesare</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>General Surgery Unit 3, Azienda Ospedaliera di Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fassan</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Advanced Translational Research, Veneto Institute of Oncology IOV, IRCCS, Padua, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pathology Unit, Department of Medicine (DIMED), University of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dei Tos</LastName><ForeName>Angelo Paolo</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Pathology Unit, Department of Medicine (DIMED), University of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Inc&#xe0;</LastName><ForeName>Renata</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Gastroenterology Unit, Azienda Ospedaliera di Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savarino</LastName><ForeName>Edoardo Vincenzo</ForeName><Initials>EV</Initials><AffiliationInfo><Affiliation>Gastroenterology Unit, Azienda Ospedaliera di Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zingone</LastName><ForeName>Fabiana</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Gastroenterology Unit, Azienda Ospedaliera di Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pucciarelli</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>General Surgery Unit 3, Azienda Ospedaliera di Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bardini</LastName><ForeName>Romeo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>General Surgery Unit 3, Azienda Ospedaliera di Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castagliuolo</LastName><ForeName>Ignazio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Microbiology Unit, Department of Molecular Medicine (DMM), University of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scarpa</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0217-6523</Identifier><AffiliationInfo><Affiliation>General Surgery Unit 3, Azienda Ospedaliera di Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>126547-89-5</RegistryNumber><NameOfSubstance UI="D018799">Intercellular Adhesion Molecule-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019409">Interleukin-15</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.17</RegistryNumber><NameOfSubstance UI="D019278">Matrix Metalloproteinase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051195">Toll-Like Receptor 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051198">Toll-Like Receptor 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>187348-17-0</RegistryNumber><NameOfSubstance UI="D018664">Interleukin-12</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053759">Interleukin-23</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C406407">DEFB1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D023083">beta-Defensins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018799" MajorTopicYN="Y">Intercellular Adhesion Molecule-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019409" MajorTopicYN="N">Interleukin-15</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020381" MajorTopicYN="N">Interleukin-17</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019278" MajorTopicYN="N">Matrix Metalloproteinase 3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="Y">Crohn Disease</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051195" MajorTopicYN="N">Toll-Like Receptor 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051197" MajorTopicYN="N">Toll-Like Receptor 4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051198" MajorTopicYN="N">Toll-Like Receptor 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018664" MajorTopicYN="N">Interleukin-12</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053759" MajorTopicYN="N">Interleukin-23</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023083" MajorTopicYN="Y">beta-Defensins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>6</Day><Hour>13</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>6</Day><Hour>12</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38319717</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003145</ArticleId><ArticleId IdType="pii">00003453-202405000-00013</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gomoll&#xf3;n F, Dignass A, Annese V, et al.; ECCO. 3rd European evidence-based consensus on the diagnosis and management of Crohn&#x2019;s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3&#x2013;25.</Citation></Reference><Reference><Citation>Geltzeiler CB, Hart KD, Lu KC, Deveney KE, Herzig DO, Tsikitis VL. Trends in the surgical management of Crohn&#x2019;s disease. J Gastrointest Surg. 2015;19:1862&#x2013;1868.</Citation></Reference><Reference><Citation>Ponsioen CY, de Groof EJ, Eshuis EJ, et al.; LIR!C study group. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn&#x2019;s disease: a randomized controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol. 2017;2:785&#x2013;792.</Citation></Reference><Reference><Citation>de Groof EJ, Stevens TW, Eshuis EJ, et al.; LIR!C study group. Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn&#x2019;s disease: the LIR!C trial. Gut. 2019;68:1774&#x2013;1780.</Citation></Reference><Reference><Citation>Stevens TW, Haasnoot ML, D&#x2019;Haens GR, et al.; LIR!C study group. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn&#x2019;s disease: retrospective long-term follow-up of the LIR!C trial. Lancet Gastroenterol Hepatol. 2020;5:900&#x2013;907.</Citation></Reference><Reference><Citation>Kelm M, Anger F, Eichlinger R, et al. Early ileocecal resection is an effective therapy in isolated Crohn&#x2019;s disease. J Clin Med. 2021;10:731.</Citation></Reference><Reference><Citation>Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease course for children newly diagnosed with Crohn&#x2019;s disease: a multicentre inception cohort study. Lancet. 2017;389:1710&#x2013;1718.</Citation></Reference><Reference><Citation>Forkel M, van Tol S, H&#xf6;&#xf6;g C, Micha&#xeb;lsson J, Almer S, Mj&#xf6;sberg J. Distinct alterations in the composition of mucosal innate lymphoid cells in newly diagnosed and established Crohn&#x2019;s disease and ulcerative colitis. J Crohns Colitis. 2019;13:67&#x2013;78.</Citation></Reference><Reference><Citation>Weizman OE, Adams NM, Schuster IS, et al. ILC1 confer early host protection at initial sites of viral infection. Cell. 2017;171:795&#x2013;808.e12.</Citation></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344&#x2013;349.</Citation></Reference><Reference><Citation>Harvey RF, Bradshaw JM. A simple index of Crohn&#x2019;s disease activity. Lancet. 1980;1:514.</Citation></Reference><Reference><Citation>Tielbeek JAW, Ziech MLW, Li Z, et al. Evaluation of conventional, dynamic contrast-enhanced and diffusion-weighted MRI for quantitative Crohn&#x2019;s disease assessment with histopathology of surgical specimens. Eur Radiol. 2014;24:619&#x2013;629.</Citation></Reference><Reference><Citation>Verstockt S, De Hertogh G, Van der Goten J, et al. Gene and miRNA regulatory networks during different stages of Crohn&#x2019;s disease. J Crohns Colitis. 2019;13:916&#x2013;930.</Citation></Reference><Reference><Citation>Daperno M, D&#x2019;Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn&#x2019;s disease: the SES-CD. Gastrointest Endosc. 2004;60:505&#x2013;512.</Citation></Reference><Reference><Citation>Team RCR. A language and environment for statistical computing. https://www.R-project.org . Accessed May 15, 2023.</Citation></Reference><Reference><Citation>Magro F, Langner C, Driessen A, et al.; European Society of Pathology (ESP). European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013;7:827&#x2013;851.</Citation></Reference><Reference><Citation>Wehkamp J, Fellermann K, Stange EF. Human defensins in Crohn&#x2019;s disease. Chem Immunol Allergy. 2005;86:42&#x2013;54.</Citation></Reference><Reference><Citation>Wehkamp J, Harder J, Weichenthal M, et al. Inducible and constitutive beta-defensins are differentially expressed in Crohn&#x2019;s disease and ulcerative colitis. Inflamm Bowel Dis. 2003;9:215&#x2013;223.</Citation></Reference><Reference><Citation>Aldhous MC, Noble CL, Satsangi J. Dysregulation of human beta-defensin-2 protein in inflammatory bowel disease. PLoS One. 2009;4:e6285.</Citation></Reference><Reference><Citation>Simms LA, Doecke JD, Walsh MD, Huang N, Fowler EV, Radford-Smith GL. Reduced alpha-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn&#x2019;s disease. Gut. 2008;57:903&#x2013;910.</Citation></Reference><Reference><Citation>Stebe-Frick S, Ostaff MJ, Stange EF, Malek NP, Wehkamp J. Histone deacetylase-mediated regulation of the antimicrobial peptide hBD2 differs in intestinal cell lines and cultured tissue. Sci Rep. 2018;8:12886.</Citation></Reference><Reference><Citation>Wehkamp J, Fellermann K, Herrlinger KR, et al. Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in the colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2002;14:745&#x2013;752.</Citation></Reference><Reference><Citation>Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A. Tumor-associated macrophages and neutrophils in tumor progression. J Cell Physiol. 2013;228:1404&#x2013;1412.</Citation></Reference><Reference><Citation>Franz&#xe8; E, Caruso R, Stolfi C, et al. Lesional accumulation of CD163-expressing cells in the gut of patients with inflammatory bowel disease. PLoS One. 2013;8:e69839.</Citation></Reference><Reference><Citation>Barros MHM, Hauck F, Dreyer JH, Kempkes B, Niedobitek G. Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages. PLoS One. 2013;8:e80908.</Citation></Reference><Reference><Citation>Lourenssen SR, Blennerhassett MG. M2 macrophages and phenotypic modulation of intestinal smooth muscle cells characterize inflammatory stricture formation in rats. Am J Pathol. 2020;190:1843&#x2013;1858.</Citation></Reference><Reference><Citation>Kredel LI, Batra A, Stroh T, et al. Adipokines from local fat cells shape the macrophage compartment of the creeping fat in Crohn&#x2019;s disease. Gut. 2013;62:852&#x2013;862.</Citation></Reference><Reference><Citation>Schulthess J, Meresse B, Ramiro-Puig E, et al. Interleukin-15-dependent NKp46+ innate lymphoid cells control intestinal inflammation by recruiting inflammatory monocytes. Immunity. 2012;37:108&#x2013;121.</Citation></Reference><Reference><Citation>Liu Z, Geboes K, Colpaert S, D&#x2019;Haens GR, Rutgeerts P, Ceuppens JL. IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production. J Immunol. 2000;164:3608&#x2013;3615.</Citation></Reference><Reference><Citation>Bouchaud G, Mortier E, Flamant M, et al. Interleukin-15 and its soluble receptor mediate the response to infliximab in patients with Crohn&#x2019;s disease. Gastroenterology. 2010;138:2378&#x2013;2387.</Citation></Reference><Reference><Citation>Silva MA, Menezes J, Deslandres C, Seidman EG. Anti-inflammatory role of interleukin-15 in Crohn&#x2019;s disease. Inflamm Bowel Dis. 2005;11:219&#x2013;230.</Citation></Reference><Reference><Citation>Vivier E, Artis D, Colonna M, et al. Innate lymphoid cells: 10 years on. Cell. 2018;174:1054&#x2013;1066.</Citation></Reference><Reference><Citation>Jowett GM, Norman MDA, Yu TTL, et al. ILC1 drive intestinal epithelial and matrix remodeling. Nat Mater. 2021;20:250&#x2013;259.</Citation></Reference><Reference><Citation>Grimm MC, Doe WF. Chemokines in inflammatory bowel disease mucosa: expression of RANTES, macrophage inflammatory protein (MIP)-1&#x3b1;, MIP-1&#x3b2;, and &#x3b3;-interferon-inducible protein-10 by macrophages, lymphocytes, endothelial cells, and granulomas. Inflamm Bowel Dis. 1996;2:88&#x2013;96.</Citation></Reference><Reference><Citation>Geremia A, Biancheri P, Allan P, Corazza GR, Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev. 2014;13:3&#x2013;10.</Citation></Reference><Reference><Citation>Sarra M, Pallone F, Macdonald TT, Monteleone G. IL-23/IL-17 axis in IBD. Inflamm Bowel Dis. 2010;16:1808&#x2013;1813.</Citation></Reference><Reference><Citation>Rosenzwajg M, Lorenzon R, Cacoub P, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2019;78:209&#x2013;217.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37643197</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Identification of MKI67, TPR , and TCHH Mutations as Prognostic Biomarkers for Patients With Defective Mismatch Repair Colon Cancer Stage II/III.</ArticleTitle><Pagination><StartPage>1481</StartPage><EndPage>1491</EndPage><MedlinePgn>1481-1491</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002734</ELocationID><Abstract><AbstractText Label="BACKGROUND">Stage II/III disease is the most predominant form of colorectal cancer, accounting for approximately 70% of cases. Furthermore, approximately 15% to 20% of patients with stage II/III disease have deficient mismatch repair or microsatellite instability-high colorectal cancer. However, there are no identified significant prognostic biomarkers for this disease.</AbstractText><AbstractText Label="OBJECTIVE">To identify prognostic markers for patients with deficient mismatch repair/microsatellite instability-high colon cancer stage II/III.</AbstractText><AbstractText Label="DESIGN">Retrospective study design.</AbstractText><AbstractText Label="SETTING">The study was conducted at a high-volume colorectal center, the Cancer Hospital, Chinese Academy of Medical Sciences.</AbstractText><AbstractText Label="PATIENTS">Patients diagnosed with stage II/III deficient mismatch repair/microsatellite instability-high colon cancer who underwent curative surgery at the Cancer Hospital at the Chinese Academy of Medical Sciences between July 2015 and November 2018 were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The primary outcome measure was the influence of differentially mutated genes on progression-free survival.</AbstractText><AbstractText Label="RESULTS">The retrospective deficient mismatch repair/microsatellite instability-high cohort involved 32 patients and The Cancer Genome Atlas-microsatellite instability-high cohort involved 45 patients. Patients with deficient mismatch repair/microsatellite instability-high colon cancer had higher mutational frequencies of MKI67 , TPR , and TCHH than patients with microsatellite stable colon cancer. MKI67 , TPR , TCHH , and gene combination were significantly correlated with prognosis. The biomarker mutation-type colon cancer group had a higher risk of recurrence or death than did the wild-type group. Moreover, biomarker mutation-type tumors had more mutations in the DNA damage repair pathway and tumor mutational burden than did biomarker wild-type tumors.</AbstractText><AbstractText Label="LIMITATIONS">This study was limited by its retrospective nature.</AbstractText><AbstractText Label="CONCLUSIONS">MKI67 , TPR , and TCHH may serve as potential diagnostic and prognostic biomarkers for deficient mismatch repair/microsatellite instability-high colon cancer stage II/III.</AbstractText><AbstractText Label="IDENTIFICACIN DE MUTACIONES MKI, TPR Y TCHH COMO BIOMARCADORES PRONSTICOS PARA PACIENTES CON CNCER DE COLON EN ETAPA II/III CON DEFICIENCIA EN LA REPARACION DE ERRORES DE EMPAREJAMIENTO">ANTECEDENTES:La enfermedad en estadio II/III es la forma m&#xe1;s predominante de c&#xe1;ncer colorrectal y representa aproximadamente el 70% de los casos. Adem&#xe1;s, aproximadamente entre el 15% y el 20% de los pacientes con enfermedad en estadio II/III tienen reparaci&#xf3;n deficiente de errores de emparejamiento o inestabilidad de microsat&#xe9;lital alta. Sin embargo, no se han identificado biomarcadores pron&#xf3;sticos significativos para esta enfermedad.OBJETIVO:Este estudio tuvo como objetivo identificar marcadores pron&#xf3;sticos para pacientes con c&#xe1;ncer de colon con reparaci&#xf3;n deficiente de errores de emparejamiento/inestabilidad microsatelital alta en estadio II/III.DISE&#xd1;O:Dise&#xf1;o de estudio retrospectivo.ESCENARIO:El estudio se realiz&#xf3; en un centro colorrectal de alto volumen, el Hospital del C&#xe1;ncer de la Academia China de Ciencias M&#xe9;dicas.PACIENTES:Pacientes diagnosticados con c&#xe1;ncer de colon en estadio II/III con reparaci&#xf3;n deficiente de errores de emparejamiento o inestabilidad de microsat&#xe9;lital alta que se sometieron a cirug&#xed;a curativa en el Hospital del C&#xe1;ncer de la Academia China de Ciencias M&#xe9;dicas entre julio de 2015 y noviembre de 2018.MEDIDAS DE RESULTADO PRINCIPALES:La medida de resultado primaria fue la influencia de los genes con mutaciones diferenciales en la supervivencia libre de progresi&#xf3;n.RESULTADOS:La cohorte retrospectiva de reparaci&#xf3;n deficiente de errores de emparejamiento o inestabilidad de microsat&#xe9;lital alta y la cohorte de inestabilidad microsatelital alta del Atlas del Genoma del C&#xe1;ncer involucraron a 32 y 45 pacientes, respectivamente. Los pacientes con de reparaci&#xf3;n deficiente de errores de emparejamiento/inestabilidad microsat&#xe9;lital alta tuvieron frecuencias mutacionales m&#xe1;s altas de MKI67 , TPR y TCHH que los pacientes estables de microsat&#xe9;lites. MKI67 , TPR , TCHH , y la combinaci&#xf3;n de genes se correlacionaron significativamente con el pron&#xf3;stico. El grupo de c&#xe1;ncer de colon de tipo mutaci&#xf3;n de biomarcador ten&#xed;a un mayor riesgo de recurrencia o muerte que el grupo de mutaci&#xf3;n salvaje. Adem&#xe1;s, los tumores de tipo mutaci&#xf3;n de biomarcadores ten&#xed;an m&#xe1;s mutaciones en la v&#xed;a de reparaci&#xf3;n del da&#xf1;o del ADN y la carga mutacional del tumor que los tumores de tipo salvaje de biomarcadores.LIMITACIONES:Este estudio estuvo limitado por su naturaleza retrospectiva.CONCLUSIONES:MKI67 , TPR , y TCHH pueden servir como posibles biomarcadores de diagn&#xf3;stico y pron&#xf3;stico para c&#xe1;ncer de colon en estadio II/III con reparaci&#xf3;n deficiente de errores de emparejamiento/inestabilidad microsat&#xe9;lital alta. (Traducci&#xf3;n-Dr. Jorge Silva Velazco ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Jingfang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wenbin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pathology, National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xintong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>ChosenMed Technology (Beijing) Co., Ltd., Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology, National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dongliang</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>ChosenMed Technology (Beijing) Co., Ltd., Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yiran</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>ChosenMed Technology (Beijing) Co., Ltd., Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Tianli</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Beifang</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>ChosenMed Technology (Beijing) Co., Ltd., Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Computer Network Information Center, Chinese Academy of Sciences, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of the Chinese Academy of Sciences, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xishan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2021-RC310-009</GrantID><Agency>Special Funds for the Basic Research and Development Program in the Central Non-profit Research Institutes of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000941">Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007381">Intermediate Filament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C479420">TCHH protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000628856">MKI67 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019394">Ki-67 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C073597">TPR protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000941" MajorTopicYN="N">Antigens</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003110" MajorTopicYN="Y">Colonic Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053843" MajorTopicYN="Y">DNA Mismatch Repair</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007381" MajorTopicYN="N">Intermediate Filament Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053842" MajorTopicYN="N">Microsatellite Instability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019394" MajorTopicYN="N">Ki-67 Antigen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>29</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>29</Day><Hour>13</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37643197</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002734</ArticleId><ArticleId IdType="pii">00003453-202311000-00013</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209&#x2013;249.</Citation></Reference><Reference><Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7&#x2013;30.</Citation></Reference><Reference><Citation>Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383:1490&#x2013;1502.</Citation></Reference><Reference><Citation>Benson AB, Venook AP, Al-Hawary MM, et al. NCCN guidelines insights: Colon cancer, version 2.2018. J Natl Compr Canc Netw. 2018;16:359&#x2013;369.</Citation></Reference><Reference><Citation>L&#xf3;pez-Correa PE, Lino-Silva LS, Gamboa-Dom&#xed;nguez A, Zepeda-Najar C, Salcedo-Hern&#xe1;ndez RA. Frequency of defective mismatch repair system in a series of consecutive cases of colorectal cancer in a national cancer center. J Gastrointest Cancer. 2018;49:379&#x2013;384.</Citation></Reference><Reference><Citation>Andr&#xe9; T, Shiu KK, Kim TW, et al.; KEYNOTE-177 Investigators. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207&#x2013;2218.</Citation></Reference><Reference><Citation>Merok MA, Ahlquist T, R&#xf8;yrvik EC, et al. Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series. Ann Oncol. 2013;24:1274&#x2013;1282.</Citation></Reference><Reference><Citation>Samowitz WS, Curtin K, Ma KN, et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev. 2001;10:917&#x2013;923.</Citation></Reference><Reference><Citation>Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer [published correction appears in J Clin Oncol . 2011;29(21):2949]. J Clin Oncol. 2011;29:1261&#x2013;1270.</Citation></Reference><Reference><Citation>Kim CG, Ahn JB, Jung M, et al. Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. Br J Cancer. 2016;115:25&#x2013;33.</Citation></Reference><Reference><Citation>Niu B, Ye K, Zhang Q, et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics. 2014;30:1015&#x2013;1016.</Citation></Reference><Reference><Citation>Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754&#x2013;1760.</Citation></Reference><Reference><Citation>Van der Auwera GA, Carneiro MO, Hartl C, et al. From FastQ data to high confidence variant calls: the genome analysis toolkit best practices pipeline. Curr Protoc Bioinformatics. 2013;43:11.10.1&#x2013;11.10.33.</Citation></Reference><Reference><Citation>Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213&#x2013;219.</Citation></Reference><Reference><Citation>Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29:308&#x2013;311.</Citation></Reference><Reference><Citation>Howie B, Marchini J, Stephens M. Genotype imputation with thousands of genomes. G3 (Bethesda). 2011;1:457&#x2013;470.</Citation></Reference><Reference><Citation>Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747&#x2013;1756.</Citation></Reference><Reference><Citation>Sveen A, Agesen TH, Nesbakken A, Rognum TO, Lothe RA, Skotheim RI. Transcriptome instability in colorectal cancer identified by exon microarray analyses: associations with splicing factor expression levels and patient survival. Genome Med. 2011;3:32.</Citation></Reference><Reference><Citation>Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243&#x2013;259.</Citation></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57:289&#x2013;300.</Citation></Reference><Reference><Citation>Gilbert LA, Hemann MT. DNA damage-mediated induction of a chemoresistant niche. Cell. 2010;143:355&#x2013;366.</Citation></Reference><Reference><Citation>Lin A, Xu W, Luo P, Zhang J. Mutations status of chemokine signaling pathway predict prognosis of immune checkpoint inhibitors in colon adenocarcinoma. Front Pharmacol. 2021;12:721181.</Citation></Reference><Reference><Citation>U Basmanav FB, Cau L, Tafazzoli A, et al. Mutations in three genes encoding proteins involved in hair shaft formation cause uncombable hair syndrome. Am J Hum Genet. 2016;99:1292&#x2013;1304.</Citation></Reference><Reference><Citation>Chen S, Liu T, Bu D, et al. Methylome profiling identifies TCHH methylation in CfDNA as a noninvasive marker of liver metastasis in colorectal cancer. FASEB J. 2021;35:e21720.</Citation></Reference><Reference><Citation>Shi J, Jiang D, Yang S, et al. Molecular profile reveals immune-associated markers of lymphatic invasion in human colon adenocarcinoma. Int Immunopharmacol. 2020;83:106402.</Citation></Reference><Reference><Citation>Gallardo P, Salas-Pino S, Daga RR. A new role for the nuclear basket network. Microb Cell. 2017;4:423&#x2013;425.</Citation></Reference><Reference><Citation>Nakano H, Funasaka T, Hashizume C, Wong RW. Nucleoporin translocated promoter region (Tpr) associates with dynein complex, preventing chromosome lagging formation during mitosis. J Biol Chem. 2010;285:10841&#x2013;10849.</Citation></Reference><Reference><Citation>Prasad ML, Vyas M, Horne MJ, et al. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer. 2016;122:1097&#x2013;1107.</Citation></Reference><Reference><Citation>Yu J, Miehlke S, Ebert MP, et al. Frequency of TPR-MET rearrangement in patients with gastric carcinoma and in first-degree relatives. Cancer. 2000;88:1801&#x2013;1806.</Citation></Reference><Reference><Citation>Moon SW, Mo HY, Choi EJ, Yoo NJ, Lee SH. Cancer-related SRCAP and TPR mutations in colon cancers. Pathol Res Pract. 2021;217:153292.</Citation></Reference><Reference><Citation>Song J, Yu Z, Dong B, et al. Clinical significance of circulating tumour cells and Ki-67 in renal cell carcinoma. World J Surg Oncol. 2021;19:156.</Citation></Reference><Reference><Citation>de Gregorio A, Friedl TWP, Hering E, et al. Ki67 as proliferative marker in patients with early breast cancer and its association with clinicopathological factors. Oncology (Huntingt). 2021;99:780&#x2013;789.</Citation></Reference><Reference><Citation>Hsieh P, Yamane K. DNA mismatch repair: molecular mechanism, cancer, and ageing. Mech Ageing Dev. 2008;129:391&#x2013;407.</Citation></Reference><Reference><Citation>Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15:81&#x2013;94.</Citation></Reference><Reference><Citation>Peltom&#xe4;ki P. Lynch syndrome genes. Fam Cancer. 2005;4:227&#x2013;232.</Citation></Reference><Reference><Citation>Kempers MJ, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol. 2011;12:49&#x2013;55.</Citation></Reference><Reference><Citation>Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26:5783&#x2013;5788.</Citation></Reference><Reference><Citation>Nakayama Y, Iijima T, Inokuchi T, et al. Clinicopathological features of sporadic MSI colorectal cancer and Lynch syndrome: a single-center retrospective cohort study. Int J Clin Oncol. 2021;26:1881&#x2013;1889.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37311698</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Cost-Effectiveness Analysis: Selective Use of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.</ArticleTitle><Pagination><StartPage>946</StartPage><EndPage>956</EndPage><MedlinePgn>946-956</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002673</ELocationID><Abstract><AbstractText Label="BACKGROUND">Locally advanced rectal cancer has high cure rates with trimodal therapy. Studies sparing neoadjuvant chemoradiation in selected patients show comparable outcomes.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to determine the cost-effectiveness of selective use of neoadjuvant chemoradiation in this population.</AbstractText><AbstractText Label="DESIGN">A cost-effectiveness analysis model compared selective and blanket use chemoradiation for locally advanced rectal cancer.</AbstractText><AbstractText Label="SETTINGS">Literature review, expert consensus, and a prospective database populated the model. Health care utilization costs were based on information from the Centers for Medicare and Medicaid Services.</AbstractText><AbstractText Label="PATIENTS">Adult patients with stage II and III rectal cancer were selected.</AbstractText><AbstractText Label="MAIN OUTCOMES MEASURES">Primary outcomes were cost, effectiveness in quality-adjusted disease-free life years, net monetary benefit, and incremental cost-effectiveness ratios in dollars per quality-adjusted disease-free life years. Base-case 5-year disease-free survival for both strategies was 65%. One-way sensitivity analysis found the probability of 5-year disease-free survival for selective ranged between 40% and 65%. Probabilistic sensitivity analysis assessed second-order variability.</AbstractText><AbstractText Label="RESULTS">Base-case 5-year disease-free survival demonstrated selective use is dominant with lower cost and higher quality-adjusted disease-free life years. For selective use, cost is $153,176, effectiveness is 2.71 quality-adjusted life years, and net monetary benefit is -$17,564 and for blanket use cost is $176,362, effectiveness is 2.64 quality-adjusted life years, and net monetary benefit is -$44,217. One-way sensitivity analysis shows selective use is dominant for disease-free survival above 61.25% and is preferred for disease-free survival above 53.7%. Probabilistic sensitivity analysis shows selective use is optimal in 88% of the iterations for a population of 10,000 patients.</AbstractText><AbstractText Label="LIMITATIONS">Model was based on data from the literature, prospective database, and expert consensus.</AbstractText><AbstractText Label="CONCLUSION">In a population of patients with locally advanced rectal cancer with base-case disease-free survival of 65%, selective use of neoadjuvant chemoradiation is the superior strategy as long as disease-free survival in this group remains above 53%. See Video Abstract at http://links.lww.com/DCR/C199.</AbstractText><AbstractText Label="ANLISIS DE COSTOEFECTIVIDAD USO SELECTIVO DE QUIMIORRADIACIN NEOADYUVANTE EN CNCER DE RECTO LOCALMENTE AVANZADO">ANTECEDENTES:El c&#xe1;ncer de recto localmente avanzado tiene altas tasas de curaci&#xf3;n con la terapia trimodal. Los estudios que evitan la quimiorradiaci&#xf3;n neoadyuvante en pacientes seleccionados muestran resultados comparables.OBJETIVO:Determinar la relaci&#xf3;n costo-efectividad del uso selectivo de quimiorradiaci&#xf3;n neoadyuvante en esta poblaci&#xf3;n.DISE&#xd1;O:Un modelo de an&#xe1;lisis de costo-efectividad compar&#xf3; la quimiorradiaci&#xf3;n selectiva y de uso general para el c&#xe1;ncer de recto localmente avanzado.AJUSTES:Revisi&#xf3;n de literatura, consenso de expertos y una base de datos prospectiva poblaron el modelo. Los costos de utilizaci&#xf3;n de la atenci&#xf3;n m&#xe9;dica se basaron en los Centros de Servicios de Medicare y Medicaid.PACIENTES:Se seleccionaron pacientes adultos con c&#xe1;ncer de recto en estadio II y III.PRINCIPALES MEDIDAS DE RESULTADOS:Los resultados primarios fueron el costo, efectividad en a&#xf1;os de vida sin enfermedad ajustados por calidad, el beneficio monetario neto y la relaci&#xf3;n costo-efectividad incremental en $/a&#xf1;os de vida sin enfermedad ajustados por calidad. La supervivencia libre de enfermedad a 5 a&#xf1;os del caso base para ambas estrategias fue del 65%. El an&#xe1;lisis de sensibilidad unidireccional vari&#xf3; la probabilidad de supervivencia libre de enfermedad a 5 a&#xf1;os para uso selectivo entre 40%-65%. El an&#xe1;lisis de sensibilidad probabil&#xed;stico evalu&#xf3; la variabilidad de segundo orden.RESULTADOS:El caso base de 5 a&#xf1;os de supervivencia libre de enfermedad demostr&#xf3; que el uso selectivo es dominante con menor costo y a&#xf1;os de vida libre de enfermedad ajustados de mayor calidad. El costo, la efectividad y el beneficio monetario neto para el uso selectivo y general fueron ($153 176; 2,71 QALY; -$17 564) y ($176 362; 2,64 QALY; -$44 217). El an&#xe1;lisis de sensibilidad unidireccional demostr&#xf3; que el uso selectivo es dominante para la supervivencia sin enfermedad por encima del 61,25% y se prefiere para la supervivencia sin enfermedad por encima del 53,7%. El an&#xe1;lisis de sensibilidad probabil&#xed;stico demostr&#xf3; que el uso selectivo es &#xf3;ptimo en el 88% de las iteraciones para una poblaci&#xf3;n de 10 000 pacientes.LIMITACIONES:Modelo basado en datos de literatura, base de datos prospectiva y consenso de expertos.CONCLUSI&#xd3;N:En una poblaci&#xf3;n de pacientes con c&#xe1;ncer de recto localmente avanzado con caso base de supervivencia libre de enfermedad del 65%, el uso selectivo de quimiorradiaci&#xf3;n neoadyuvante para el c&#xe1;ncer de recto localmente avanzado es la estrategia superior, siempre y cuando la supervivencia libre de enfermedad en este grupo se mantenga por encima del 53%. Consulte Video Resumen en http://links.lww.com/DCR/C199. (Traducci&#xf3;n-Dr. Fidel Ruiz Healy).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mueller</LastName><ForeName>Andrew N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Department of Surgery, Creighton University School of Medicine, Omaha, Nebraska.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torgersen</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Surgery, Creighton University School of Medicine, Omaha, Nebraska.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shashidharan</LastName><ForeName>Maniamparampil</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, Creighton University School of Medicine, Omaha, Nebraska.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ternent</LastName><ForeName>Charles A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Surgery, Creighton University School of Medicine, Omaha, Nebraska.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006278" MajorTopicYN="N">Medicare</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016609" MajorTopicYN="Y">Neoplasms, Second Primary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>14</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>13</Day><Hour>22</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37311698</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002673</ArticleId><ArticleId IdType="pii">00003453-202307000-00014</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70:145&#x2013;164.</Citation></Reference><Reference><Citation>Brouwer NPM, Bos ACRK, Lemmens VEPP, et al. An overview of 25 years of incidence, treatment and outcome of colorectal cancer patients. Int J Cancer. 2018;143:2758&#x2013;2766.</Citation></Reference><Reference><Citation>National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Rectal Cancer. Version 1.2021. https://www.poijaya.org/wp-content/uploads/2021/08/rectal.pdf . Published 2020. Accessed March 15, 2022.</Citation></Reference><Reference><Citation>Peeters KCMJ, van de Velde CJH, Leer JWH, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients&#x2013;a Dutch colorectal cancer group study. J Clin Oncol. 2005;23:6199&#x2013;6206.</Citation></Reference><Reference><Citation>Bernstein MA. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Dis Colon Rectum. 2009;52:1532&#x2013;1533.</Citation></Reference><Reference><Citation>De Caluw&#xe9; L, Van Nieuwenhove Y, Ceelen WP. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev. 2013;2013:CD006041.</Citation></Reference><Reference><Citation>Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23:5644&#x2013;5650.</Citation></Reference><Reference><Citation>Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215&#x2013;1223.</Citation></Reference><Reference><Citation>Sauer R, Becker H, Hohenberger W, et al.; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731&#x2013;1740.</Citation></Reference><Reference><Citation>Pollack J, Holm T, Cedermark B, et al. Late adverse effects of short-course preoperative radiotherapy in rectal cancer. Br J Surg. 2006;93:1519&#x2013;1525.</Citation></Reference><Reference><Citation>Bruheim K, Guren MG, Skovlund E, et al. Late side effects and quality of life after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2010;76:1005&#x2013;1011.</Citation></Reference><Reference><Citation>Hoerske C, Weber K, Goehl J, Hohenberger W, Merkel S. Long-term outcomes and quality of life after rectal carcinoma surgery. Br J Surg. 2010;97:1295&#x2013;1303.</Citation></Reference><Reference><Citation>Marijnen CAM, van de Velde CJH, Putter H, et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol. 2005;23:1847&#x2013;1858.</Citation></Reference><Reference><Citation>Bazan JG, Koong AC, Chang DT. Rectal cancer. Med Radiol (Berl). 2015;67:303&#x2013;314.</Citation></Reference><Reference><Citation>Brown G; MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ. 2006;333:779&#x2013;782.</Citation></Reference><Reference><Citation>Brown G; MERCURY Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology. 2007;243:132&#x2013;139.</Citation></Reference><Reference><Citation>Taylor FGM, Quirke P, Heald RJ, et al.; MERCURY study. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg. 2011;253:711&#x2013;719.</Citation></Reference><Reference><Citation>Ruppert R, Junginger T, Ptok H, et al.; OCUM group. Oncological outcome after MRI-based selection for neoadjuvant chemoradiotherapy in the OCUM rectal cancer trial. Br J Surg. 2018;105:1519&#x2013;1529.</Citation></Reference><Reference><Citation>Ahmed S, Baxter N, Bouchard A, et al. Quicksilver: a phase II study using magnetic resonance imaging criteria to identify &#x201c;good prognosis&#x201d; rectal cancer patients eligible for primary surgery. JMIR Res Protoc. 2015;4:1&#x2013;10.</Citation></Reference><Reference><Citation>Glynne-Jones R, Wyrwicz L, Tiret E, et al.; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv22&#x2013;iv40.</Citation></Reference><Reference><Citation>Burton S, Brown G, Daniels IR, Norman AR, Mason B, Cunningham D; Royal Marsden Hospital, Colorectal Cancer Network. MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins? Br J Cancer. 2006;94:351&#x2013;357.</Citation></Reference><Reference><Citation>Hermanek P, Junginger T. The circumferential resection margin in rectal carcinoma surgery. Tech Coloproctol. 2005;9:193&#x2013;199.</Citation></Reference><Reference><Citation>Videhult P, Smedh K, Lundin P, Kraaz W. Magnetic resonance imaging for preoperative staging of rectal cancer in clinical practice: high accuracy in predicting circumferential margin with clinical benefit. Colorectal Dis. 2007;9:412&#x2013;419.</Citation></Reference><Reference><Citation>Strassburg J, Ruppert R, Ptok H, et al. MRI-based indications for neoadjuvant radiochemotherapy in rectal carcinoma: interim results of a prospective multicenter observational study. Ann Surg Oncol. 2011;18:2790&#x2013;2799.</Citation></Reference><Reference><Citation>Kreis ME, Ruppert R, Ptok H, et al.; OCUM study group. Use of preoperative magnetic resonance imaging to select patients with rectal cancer for neoadjuvant chemoradiation&#x2014;interim analysis of the German OCUM trial (NCT01325649). J Gastrointest Surg. 2016;20:25&#x2013;32.</Citation></Reference><Reference><Citation>Wright ME, Beaty JS, Thorson AG, Rojas R, Ternent CA. Cost-effectiveness analysis of total neoadjuvant therapy followed by radical resection versus conventional therapy for locally advanced rectal cancer. Dis Colon Rectum. 2019;62:568&#x2013;578.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>